Intas has introduced the generic version to Sanofi Aventis’s Taxotere (Docetaxel Injection) 20 mg and 80 mg in the US market. This approval was under 505(b) 2 application and was approved on 8th June, 2011. The Docetaxel Injection is Antineoplastic which is majorly used for Breast Cancer and Lung Cancer treatment. Intas is the third pharmaceutical company to launch the generic product to Taxotere. Being a billion dollar product with less competition due to the entry barrier, this launch will be a growth driver for Intas’s USA oncology and hospital operations.